Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Immutep Limited due to alleged violations of securities laws following the discontinuation of a key clinical trial, which led to a significant drop in the company's stock price [1][2]. Group 1: Investigation Details - The investigation focuses on whether Immutep issued false or misleading statements or failed to disclose important information to investors [2]. - On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa due to a planned interim futility analysis [2]. - Following this announcement, Immutep's American Depositary Receipts (ADRs) fell by more than 82.4% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights free of charge [3].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Canadian Solar Inc. due to reported losses and possible non-compliance with federal securities laws [1][4]. Group 1: Investigation Details - The investigation focuses on whether Canadian Solar's executive officers may have caused investor losses that could be recovered under federal securities laws [1]. - Investors who purchased Canadian Solar securities and suffered losses are encouraged to join the investigation [2]. Group 2: Financial Performance - On March 19, 2026, Canadian Solar announced its Q4 2025 and full-year financial results, revealing a sequential decline in key operating metrics [3]. - The company reported a double-digit percentage drop in solar module shipments and a quarter-over-quarter revenue contraction from Q3 levels, along with guidance for lower gross margins [3].

Core Viewpoint - Kyndryl Holdings, Inc. is facing securities class action lawsuits due to alleged failures in disclosing material information during the class period from August 1, 2024, to February 9, 2026, which has led to significant financial repercussions for investors [1][3]. Group 1: Lawsuit Details - Investors have until April 13, 2026, to file lead plaintiff applications in the ongoing securities class action lawsuits against Kyndryl [1]. - The lawsuits are pending in the United States District Court for the Eastern and Southern Districts of New York [1]. - The first-filed case is Brander v. Kyndryl Holdings, Inc., and a subsequent case has expanded the class period [5]. Group 2: Company Disclosures - On February 9, 2026, Kyndryl disclosed its inability to timely file its Form 10-Q Report for the quarter ended December 31, 2025, citing anticipated material weaknesses in internal controls over financial reporting [4]. - The company also reported the departure of its Chief Financial Officer and General Counsel, which contributed to a significant drop in share price [4]. - Following this disclosure, Kyndryl's share price fell by $12.90, or 55%, closing at $10.59 on February 9, 2026 [4]. Group 3: Investor Support - ClaimsFiler provides a free service for investors to access information regarding securities class action settlements and to assist in filing claims [6]. - Investors can register for free on ClaimsFiler.com to receive notifications about relevant securities cases [6].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of AirSculpt Technologies, Inc. due to significant losses reported by the company, focusing on whether these losses can be recovered under federal securities laws [1][4]. Financial Performance - On November 7, 2025, AirSculpt reported a revenue decline of approximately 17.8% year-over-year, totaling around $35 million [3]. - The company experienced a case volume decline of approximately 15.2% year-over-year and a same-store revenue decline of approximately 22% [3]. - AirSculpt reported a net loss of approximately $9.5 million for the third quarter of 2025 [3]. Market Reaction - Following the earnings call where management acknowledged that third quarter revenue was lower than anticipated, the stock price of AirSculpt Technologies declined significantly [4]. Legal Investigation - Johnson Fistel is investigating whether AirSculpt Technologies complied with federal securities laws in light of the financial disclosures and subsequent stock price decline [4].

Core Viewpoint - The Schall Law Firm is investigating Boston Scientific Corporation for potential violations of securities laws, focusing on whether the company made false or misleading statements and failed to disclose important information to investors [1] Financial Performance - Boston Scientific reported disappointing Q4 and full year 2025 results on February 4, 2026, with sales guidance for 2026 significantly below market expectations [1] - The company attributed its poor performance to slower market growth and increased competition, contradicting previous management claims of growth [1] Market Reaction - Following the announcement of the disappointing results, shares of Boston Scientific fell by more than 17% on the same day [1]

Core Viewpoint - The Schall Law Firm is investigating claims against PROCEPT BioRobotics Corporation for potential violations of securities laws due to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether PROCEPT BioRobotics issued false or misleading statements and failed to disclose critical information to investors [2]. - The company reported Q4 2025 financial results on February 25, 2026, revealing quarterly revenue significantly below analyst expectations and a substantial cut in full-year revenue guidance [2]. - The decline in performance was attributed to disruptions from a realignment and the removal of bulk-purchase discounts, leading to a more than 15.1% drop in share price the following day [2]. Group 2: Shareholder Information - Shareholders who experienced losses are encouraged to participate in the investigation and can contact the Schall Law Firm for a free discussion of their rights [3]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [3].

Core Viewpoint - The Schall Law Firm is investigating Aardvark Therapeutics, Inc. for potential violations of securities laws following a significant drop in share price due to safety concerns related to a late-stage trial pause [1][2]. Group 1: Investigation Details - The investigation focuses on whether Aardvark issued false or misleading statements or failed to disclose important information to investors [2]. - Aardvark paused its late-stage study for a rare disease treatment after discovering heart-related side effects during safety monitoring in a healthy volunteer study [2]. - Following the announcement of the trial pause, Aardvark's shares fell by over 47.3% in after-hours trading on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the firm to discuss their rights free of charge [3].

Core Viewpoint - Telesat Corporation is under investigation for potential violations of securities laws, following a lawsuit from bondholders claiming the company is insolvent and has attempted to transfer valuable assets away from creditors [1][2]. Group 1: Investigation Details - The Schall Law Firm is investigating claims on behalf of Telesat investors regarding false or misleading statements and failure to disclose important information [1][2]. - A lawsuit filed by Telesat's bondholders on January 21, 2026, alleges that the company is "indisputably insolvent" and has neglected its debt obligations [2]. Group 2: Market Reaction - Following the news of the lawsuit and investigation, Telesat's shares experienced a significant decline, falling by 21% on the same day [2].

Core Viewpoint - The Schall Law Firm is investigating claims against Gartner, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [2]. Group 1: Investigation Details - The investigation centers on whether Gartner issued false or misleading statements and failed to disclose relevant information to investors [2]. - Gartner's Q4 2025 financial results, reported on February 3, 2026, revealed that the company's 2026 revenue and earnings forecasts did not meet analyst expectations [2]. - Following the disappointing financial results, Gartner's shares experienced a significant decline, falling by more than 20.8% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses due to the alleged violations [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - The Schall Law Firm is investigating claims against Pinterest, Inc. for potential violations of securities laws following disappointing Q4 2025 financial results that led to a significant drop in share price [1][2]. Group 1: Investigation Details - The investigation centers on whether Pinterest made false or misleading statements or failed to disclose important information to investors [2]. - Following the Q4 2025 financial results announcement on February 12, 2026, Pinterest's shares fell by over 16.8% the next day due to management's dissatisfaction with revenue performance and acknowledgment of external shocks related to tariffs [2]. Group 2: Company Response - Pinterest's management expressed that the Q4 revenue performance does not reflect the company's potential and indicated a need for faster movement in response to challenges faced [2].